Learn More
Description
Gastric inhibitory polypeptide (GIP; MIM 137240), also called glucose-dependent insulinotropic polypeptide, is a 42-amino acid polypeptide synthesized by K cells of the duodenum and small intestine. It was originally identified as an activity in gut extracts that inhibited gastric acid secretion and gastrin release, but subsequently was demonstrated to stimulate insulin release potently in the presence of elevated glucose. The insulinotropic effect on pancreatic islet beta-cells was then recognized to be the principal physiologic action of GIP. Together with glucagon-like peptide-1, GIP is largely responsible for the secretion of insulin after eating. It is involved in several other facets of the anabolic response.[supplied by OMIM
Specifications
Specifications
| Antigen | GIPR |
| Applications | Immunohistochemistry (PFA fixed) |
| Classification | Polyclonal |
| Conjugate | Unconjugated |
| Description | Rabbit polyclonal antibody raised against synthetic peptide of GIPR. |
| Dilution | Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) (8-21 ug/mL) The optimal working dilution should be determined by the end user. |
| Formulation | In PBS (0.09% sodium azide) |
| Gene | GIPR |
| Gene Accession No. | P48546 |
| Gene Alias | MGC126722 |
| Show More |
For Research Use Only
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.